This study is a prospective case series aiming to evaluate a new VPIA remifentanil algorithm which would benefit labouring mothers who are unable or unwilling to receive epidural analgesia.
This study proposes a novel Vital signs-controlled, patient-assisted intravenous analgesia (VPIA) regimen that will enhance the efficacy, safety and personalization of remifentanil therapy for labouring women. This system will study the parturient's pattern of analgesic use in 15 min epochs and titrate the demand doses and basal infusion rate to maintain a plasma level of remifentanil that is appropriate for the degree of pain felt. The system incorporates vital signs (pulse oximetry and heart rate values) into the algorithm which would temporarily stop the pumps and step down doses accordingly when predefined critical values are reached.
Study Type
OBSERVATIONAL
Enrollment
29
Vital signs controlled patient assisted intravenous analgesia using remifentanil
KK Women's & Children's Hospital
Singapore, Singapore, Singapore
Pain score
Hourly maternal pain scores
Time frame: Duration of labour
Remifentanil drug consumption
Total and hourly remifentanil drug consumption.
Time frame: Duration of labour
Maternal side effects
Incidence of side effects : sedation, respiratory depression, oxygen desaturation, bradycardia, pruritus, nausea and vomiting
Time frame: Duration of labour and 1st day post delivery
Maternal outcomes
Mode of delivery Duration of second stage Overall satisfaction with labour analgesia
Time frame: Duration of labour and one day post delivery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.